We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

Blood Test for Multiple Pathways Related to Alzheimer’s Could Enable Earlier and Less-Invasive Diagnosis

By LabMedica International staff writers
Posted on 31 Mar 2023
Print article
Image: New research by neuroscientists will lay the groundwork for Alzheimer’s disease precision medicine (Photo courtesy of Pexels)
Image: New research by neuroscientists will lay the groundwork for Alzheimer’s disease precision medicine (Photo courtesy of Pexels)

A five-year, USD 41 million study, titled Centrally-linked Longitudinal Peripheral Biomarkers of AD, or CLEAR-AD, that involves over 40 experts and 13 institutions across the U.S. and abroad, will facilitate collaboration and promote progress in Alzheimer's disease research through several innovative approaches. By combining sophisticated single-cell analysis of human brain tissue with neuroimaging and blood-based biomarker research, CLEAR-AD aims to generate extensive data that will enable researchers to advance precision medicine for Alzheimer's patients.

Researchers at Indiana University School of Medicine (Indianapolis, IN, USA) are co-leading are co-leading the CLEAR-AD study to gain a deeper understanding of the biological mechanisms involved in Alzheimer's disease. The ultimate goal of the study is to provide personalized care to patients by developing a blood test for multiple pathways associated with the disease, which will enable earlier and less-invasive diagnosis. The CLEAR-AD study consists of three interconnected projects that will help researchers devise innovative approaches to understand and diagnose a disease that has affected millions of lives, particularly African American and Hispanic communities. The study's findings will be swiftly disseminated among the scientific community to expedite collaborative progress.

The CLEAR-AD study consists of three projects, with the first project utilizing cutting-edge single cell and single nucleus sequencing to investigate gene expression discrepancies among various types of brain cells in up to seven brain regions. This will result in an unparalleled database of molecular signatures linking the brain and blood, which can be further analyzed by the research community. The second project will focus on a longitudinal examination of endophenotypes, measurable biological traits associated with Alzheimer's disease, which can be studied through MRI and PET brain imaging, fluid biomarkers, and cognitive performance tests. The molecular signatures from brain cells in project one will be linked to Alzheimer's disease characteristics such as cognitive decline, cortical thickness and hippocampal volume loss on MRI, and amyloid plaque and tau tangles accumulation on brain PET scans. These efforts are expected to provide novel insights into the disease's stage-specific progression and identify potential therapeutic targets.

The third project of the CLEAR-AD study aims to fill the existing knowledge gaps in Alzheimer's disease research among multi-ethnic populations. It will connect the molecular signatures and endophenotypes from the first two projects with patterns observed among African American and Hispanic participants. This is crucial because African American and Hispanic populations are more susceptible to developing the disease, yet less likely to receive a diagnosis. Most prior research has predominantly focused on data from white participants of European ancestry, resulting in a lack of knowledge about how the disease affects African American and Hispanic populations. CLEAR-AD aims to address this issue by developing and validating advanced diagnostic tools that can support diverse populations in accessible ways. The study will collaborate with local communities across the US to identify differences in Alzheimer's disease genes and endophenotypes, including imaging, cognition, and blood biomarkers, between African American and Hispanic populations and their white counterparts.

“While we currently have very powerful and informative measures for Alzheimer’s diagnosis, most are slightly invasive and focused on amyloid plaques and tau tangles,” said Andrew Saykin, PsyD, director of the Indiana Alzheimer’s Disease Research Center and the IU Center for Neuroimaging and one of the four principal investigators on the study. “CLEAR-AD will use a systems biology approach to better understand those factors that drive these pathological hallmarks in the first place. There has been great recent progress with the development of blood tests, but assessing multiple biological pathways earlier and noninvasively could make diagnosis more accessible and treatment plans more individually tailored for each patient.”

“CLEAR-AD will allow us to connect what we see in peripheral blood and on imaging to what we see in brain tissue, which will be paramount in the opportunity to create the next generation of blood tests to diagnose individuals with Alzheimer’s disease even earlier when the disease is most treatable,” said Kwangsik Nho, PhD, associate professor of radiology and imaging sciences at IU School of Medicine and another principal investigator of CLEAR-AD who is leading the second project.

Related Links:
Indiana University School of Medicine

Flocked Swab
HydraFlock and PurFlock Ultra
Platinum Supplier
Automatic Nucleic Acid Extractor
GeneFlex 16n
New
Auto Clinical Chemistry Analyzer
ChemiLab 100
New
Semi-Automatic Biochemistry Analyzer
CA-80

Print article

Channels

Clinical Chem.

view channel
Image: Electrochemical cells etched by laser on wooden tongue depressor measure glucose and nitrite in saliva (Photo courtesy of Analytical Chemistry)

Biosensor-Fabricated Wooden Tongue Depressor Measures Glucose and Nitrite in Saliva

Physicians often use tongue depressors to examine a patient's mouth and throat. However, it is hard to imagine that this simple wooden tool could actively assess a patient's health. This idea has led to... Read more

Hematology

view channel
Image: The Atellica HEMA 570 and 580 hematology analyzers remove workflow barriers (Photo courtesy of Siemens)

Next-Gen Hematology Analyzers Eliminate Workflow Roadblocks and Achieve Fast Throughput

Hematology testing is a critical aspect of patient care, utilized to establish a patient's health baseline, track treatment progress, or guide timely modifications to care. However, increasing constraints... Read more

Immunology

view channel
Image: Newly observed anti-FSP antibodies have also been found to predict immune-related adverse events (Photo courtesy of Calviri)

First Blood-Based Biomarkers Test to Predict Treatment Response in Cancer Patients

Every year worldwide, lung cancer afflicts over two million individuals and almost the same number of people succumb to the disease. This malignancy leads the charts in cancer-related mortalities, with... Read more

Microbiology

view channel
Image: The rapid MTB strip test for tuberculosis can identify TB patients within two hours (Photo courtesy of Chulalongkorn University)

Rapid MTB Strip Test Detects Tuberculosis in Less Than an Hour without Special Tools

Tuberculosis (TB), a highly infectious disease, continues to pose significant challenges to public health worldwide. TB is caused by a bacterium known as "Mycobacterium tuberculosis," spreading through... Read more

Pathology

view channel
Image: The UNIQO 160 (CE-IVDR) advances diagnostic analysis for autoimmune diseases (Photo courtesy of EUROIMMUN)

Novel Automated IIFT System Enables Cutting-Edge Diagnostic Analysis

A newly-launched automated indirect immunofluorescence test (IIFT) system for autoimmune disease diagnostics offers an all-in-one solution to enhance the efficiency of the complete IIFT process, comprising... Read more

Technology

view channel
Electronic biosensor uses DNA aptamers for detecting biomarkers in whole blood samples (Photo courtesy of Freepik)

Electronic Biosensor Detects Biomarkers in Whole Blood Samples without Addition of Reagents

The absence of robust, reliable, and user-friendly bioanalytical tools for early and timely diagnosis of cardiovascular diseases, particularly sudden cardiac arrest, leads to preventable deaths and imposes... Read more

Industry

view channel
Image: The global hemostasis diagnostics market is expected to reach USD 3.95 billion by 2025 (Photo courtesy of Freepik)

Global Hemostasis Diagnostics Market Driven by Increase in Invasive Surgical Procedures

Injury or surgery naturally creates bleeding in living beings, which must be stopped to prevent excessive blood loss. The human body implements a protective mechanism known as hemostasis to stop excessive bleeding.... Read more
Copyright © 2000-2023 Globetech Media. All rights reserved.